The current study was performed to examine temporal trends and compare overall survival (OS) in patients undergoing radical cystectomy (RC) or bladder-preservation therapy (BPT) for muscle-invasive urothelial carcinoma of the bladder. METH-ODS: The authors reviewed the National Cancer Data Base to identify patients with AJCC stage II to III urothelial carcinoma of the bladder from 2004 through 2013. Patients receiving BPT were stratified as having received any external-beam radiotherapy (any XRT), definitive XRT (50-80 grays), and definitive XRT with chemotherapy (CRT). Treatment trends and OS outcomes for the BPT and RC cohorts were evaluated using Cochran-Armitage tests, unadjusted Kaplan-Meier curves, adjusted Cox multivariate regression, and propensity score matching, using increasingly stringent selection criteria. RESULTS: A total of 32,300 patients met the inclusion criteria and were treated with RC (22,680 patients) or BPT (9620 patients). Of the patients treated with BPT, 26.4% (2540 patients) and 15.5% (1489 patients), respectively, were treated with definitive XRT and CRT. Improved OS was observed for RC in all groups. After adjustments with more rigorous statistical models controlling for confounders and with more restrictive BPT cohorts, the magnitude of the OS benefit became attenuated on multivariate (any XRT: hazard ratio 
INTRODUCTION
In 2017, approximately 79,000 new cases of bladder cancer are expected to be diagnosed in the United States, leading to an estimated 17,000 cancer-specific deaths. 1 Although mortality rates are improving, approximately 20% to 30% of patients are diagnosed with de novo muscle-invasive disease, which carries a 24-month overall survival (OS) without treatment. 1, 2 In contemporary best practice guidelines, the therapeutic mainstay of treatment with category 1 evidence for muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) with bilateral pelvic lymph node dissection and urinary diversion 3 ; however, this treatment is associated with significant procedure-related morbidity. 4, 5 Accordingly, a 2013 retrospective cohort analysis of the National Cancer Data Base (NCDB) demonstrated that only 52.5% of patients with AJCC stage II to IV bladder cancer received treatment with aggressive therapy with curative intent (partial or RC or definitive chemoradiotherapy). 6 Trimodal bladder-preservation therapy (BPT) with maximal transurethral resection (TUR), chemotherapy, and radiotherapy (XRT) is an alternative treatment option in appropriately selected patients who are unfit or unwilling to undergo RC. 3 Advantages of BPT include avoiding the short-term and long-term morbidity of a complex operation, maintaining the patients' native bladder, and improved quality of life. 7, 8 Although well-designed studies have demonstrated improved 10-year locoregional control when comparing chemoradiotherapy with XRT alone, 9, 10 to the best of our knowledge no prospective or randomized controlled trials have been performed to date comparing survival outcomes of patients treated with BPT with those of patients receiving RC. 3, 7, 8 Existing data comparing RC with BPT modalities are comprised of retrospective institutional cohorts or observational studies. Both are hindered by selection biases and to our knowledge there are little data describing what percentage of patients treated with BPT actually receive optimal trimodal therapy outside of clinical trials. 7, 11, 12 Contemporary utilization trends of BPT have been poorly characterized, and there are limited data regarding survival outcomes. Using a large national tumor registry, the objectives of the current study were to examine temporal trends in the use of BPT and compare survival outcomes of patients with stage II to III urothelial carcinoma of the bladder who were treated with RC and BPT using multiple statistical methods to adjust for measurable differences between treatment groups.
MATERIALS AND METHODS

Data Source
The NCDB, a program of the American College of Surgeons Commission on Cancer and the American Cancer Society, is a national cancer registry that was established in 1989 and serves as a comprehensive clinical surveillance resource for cancer care in the United States. 13, 14 The NCDB compiles data from >1500 Commission on Cancer-accredited cancer programs in the United States and Puerto Rico, capturing approximately 70% of all newly diagnosed cancer cases.
13,14
Cohort Definition
Patients with urothelial carcinoma of the bladder were identified in the NCDB based on International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) site codes C670 through C679. The current study cohort was restricted to individuals aged 18 years with analytic stage II to III (N0/M0) disease between the years of 2004 and 2013 who were treated with XRT or RC. The NCDB analytical staging variable preferentially assigns pathologic stage, unless it is not reported, in which case clinical stage is used. Patients with nonurothelial histology; stage I, IV, or unknown disease; missing survival data; and those undergoing partial cystectomy were excluded from analysis. The current analysis was restricted to patients with AJCC stage II to III disease, compliant with current National Comprehensive Cancer Network guidelines. 3 
Exposure and Outcomes
Receipt of RC was determined by surgery of the primary site codes (50-74). Receipt of BPT was defined as undergoing any XRT treatment. For study purposes, we substratified patients who received BPT who were treated with transurethral resection and: 1) any external-beam XRT (any XRT); 2) definitive XRT (defined as receiving 50-80 grays); or 3) definitive XRT with chemotherapy (CRT). Use of chemotherapy with XRT was defined as the receipt of any chemotherapy administered within 3 months of XRT.
Covariates
Patient socioeconomic characteristics were obtained from the US Census tract data. Based on case volume and access to cancer-related services and specialists, the NCDB classifies hospitals as unknown, community (100-500 new cancer cases/year), comprehensive community (>500 cases/year), and teaching/research (academic), as defined by the National Cancer Institute designation or a medical school affiliation.
Statistical Analyses
Trends in the use of BPT and RC for patients with analytic stage II to III urothelial carcinoma of the bladder were assessed from 2004 through 2013 using CochranArmitage tests for trend. Patient demographic and clinical characteristics were compared by treatment type (any XRT, definitive XRT, CRT, and RC) using Pearson chisquare tests. We then used multivariate logistic regression to assess the association between receipt of definitive XRT with chemotherapy and patient/tumor factors including age, sex, race (white, black, or other), ethnicity (Hispanic, non-Hispanic, or unknown), payer group, income quartile, education, urban/rural status, facility location, facility type, facility volume (in tertiles), histologic type, and tumor grade (1) (2) (3) (4) . To account for clustering within hospitals, we calculated robust standard errors using generalized estimating equations. 15 
Survival Analyses
OS, defined as time from RC or the end of XRT until death or loss to follow-up, was compared between patients treated with RC and each BPT cohort (any XRT, definitive XRT, and CRT) using unadjusted Kaplan-Meier curves. The association between treatment type (BPT vs RC) and OS was tested using increasingly stringent selection criteria to identify those patients undergoing BPT. We used both multivariate Cox regression models adjusting for patient and tumor characteristics as well as 1:1 matched analyses using propensity score. [16] [17] [18] To find Original Article comparable matches, patients treated with RC versus those receiving BPT were matched exactly based on age (in 5-year increments), stage, grade, and Charlson-Deyo score. Other factors were summarized using the propensity score, estimated via logistic regression, and patients were matched within propensity score calipers. We assessed balance between each covariate in the matched samples, and then conducted Cox regression models with an indicator for treatment type with stratification to account for the matched pairs. Statistical analysis was performed with SAS (version 9.3; SAS Institute Inc, Cary, NC) and R (version 3.1; R Foundation, Vienna, Austria) statistical software, in which P<.05 is considered statistically significant.
RESULTS
A total of 484,367 patients with a bladder cancer diagnosis were identified in the NCDB from 2004 to 2013. Of these, we identified 32,300 patients who met cohort inclusion criteria as described in Figure Comparing the patients treated with CRT versus those undergoing RC on univariate analysis (Table 1) , Figure 1 . Consolidated Standards Of Reporting Trials (CONSORT) flow diagram demonstrating inclusion and exclusion criteria of the study cohort. BPT indicates bladder-preservation therapy; EBRT, external-beam radiotherapy; Gy, grays; NCDB, National Cancer Data Base; RC, radical cystectomy; XRT, radiotherapy. statistically significant differences were noted with respect to age (P<.0001), race (P 5 .0027), Charlston-Deyo score (P<.0001), analytic stage of disease (P<.0001), facility type (P<.0001), urban location (P 5 .0104), and insurance payer status (P<.0001). No substantial differences were noted with regard to sex, tumor grade, Hispanic ethnicity, median income quartile, or no high school diploma quartile (all P>.05).
Using multivariable logistic regression models, we found that African American race (odds ratio [ On unadjusted, multivariate, and matched propensity score-adjusted analyses, a statistically significant OS advantage was observed for all patients treated with RC compared with those receiving BPT, regardless of the cohort definition of BPT used (all P<.0001). However, the survival benefit of RC compared with BPT was attenuated using more rigorous statistical adjustment controlling for confounding variables on univariate, multivariate, and matched propensity score-adjusted analyses (Table 2 ). In addition, when applying stricter cohort definitions (any XRT, definitive XRT, and CRT) to identify patients undergoing optimal trimodal therapy, the survival advantages of RC also were diminished, as demonstrated in Figure 3 and Table 2 .
DISCUSSION
In the current study, we observed a statistically significant OS advantage for RC compared with BPT in patients with urothelial carcinoma of the bladder that was independent of the BPT treatment protocol used. However, the survival benefit was tempered when more stringent BPT criteria were applied and using more rigorous statistical methods controlling for confounding factors. The results of the current study suggest that BPT may produce acceptable oncologic outcomes in appropriately selected patients.
Furthermore, the results of the current analysis demonstrate the challenges of using retrospective and observational cohort studies and administrative databases in the comparisons of BPT with extirpative surgery. Not only do drastically different treatment cohorts demonstrate inherent selection (confounding) biases, but underlying unmeasured biases often influence results as well. It is clear that surgeons often select more fit candidates for surgery, and reserve BPT for the frail and elderly. 19 The findings of the current study are consistent with the results of a 2013 retrospective observational Surveillance, Epidemiology, and End Results-Medicare study that demonstrated differences in survival between BPT and RC using multivariable and propensity score methods, whereas an instrumental variable analysis demonstrated no differences in survival between groups. 12 However, the current study incorporated a much larger cohort size (1843 patients vs 32,300 patients), which included an all-payer mix and patients aged <65 years. 12 Recently, long-term BPT outcomes published from a large single-center cohort at Massachusetts General Hospital of patients with cT2-4a MIBC demonstrated 5-year and 10-year OS rates of 57% and 39%, respectively, and 5-year and 10-year disease-specific survival rates of 66% and 59%, respectively. 20 These retrospective and observational cohorts highlight that BPT and RC may result in similar oncologic outcomes in appropriately selected patients. 12, 20 In the NCDB, BPT is used significantly less often than RC. Unfortunately, the administration of suboptimal therapy (subtherapeutic XRT in the absence of concurrent chemotherapy) is often the norm. BC2001, a phase 3 prospective trial, compared patients with MIBC who were treated with XRT alone versus those treated with XRT and synchronous 5-fluorouracil and mitomycin C. 9, 10 In both the initial publication and the 10-year follow-up abstract, locoregional control was found to be superior in patients receiving concurrent CRT, and a reduced salvage cystectomy rate also was noted. 9, 10 Whether with split-course or continuous- course dosing, CRT has become the standard of care for patients with BPT. 3 As supported by the findings of the current study, more stringent definitions of BPT (optimal therapies) led to improved survival compared with any XRT and definitive XRT in the absence of systemic therapy. In addition, in the current analysis, only 4.6% of the total patient cohort (15.5% of the BPT cohort) received optimal BPT (appropriately dosed CRT). The relative underuse of BPT is likely multifactorial. Retrospective analyses of the Ontario Cancer Registry demonstrated that only 32% and 18%, respectively, of MIBC patients treated with curative intent received a consultation by radiation oncology 21 and medical oncology. 22 Ideal candidates for BPT include patients with cT2-T3N0M0 disease, no carcinoma in situ present, unifocal lesions, no hydronephrosis, those in whom complete transurethral resection is possible, and those with urothelial histology. 7, 8, 23 However, a recent retrospective Abbreviations: 95% CI, 95% confidence interval; BPT, bladder-preservation therapy; HR, hazard ratio; OS, overall survival; RC, radical cystectomy; XRT, radiotherapy. single-center cohort analysis demonstrated acceptable oncologic outcomes with histologic variants treated with trimodal BPT. 24 Renal function also may influence the tolerability of BPT protocols and the specific chemotherapeutic regimen administered. A previous study estimated that only 40% of patients who underwent RC at single tertiary care referral center were eligible for BPT. 23 However, this study did not specifically assess preoperative glomerular filtration rate. 23 The differences in 5-year OS between the optimal BPT and RC cohorts (30% vs 48%) in the current study calls into question the intermediate-term to long-term viability of BPT. In patients enrolling in BPT protocols, oncologic control is fundamental, and the possibility of a future salvage cystectomy should be discussed. In addition, given the emergence of validated biomarkers predicting pathologic complete response to NAC, several groups currently are initiating trials of risk-adapted treatment for patients with MIBC. 25, 26 In these protocols, patients are treated with upfront cisplatin-based chemotherapy, and those harboring genomic alterations associated with response to systemic therapy and with no evidence of residual disease on a transurethral resection of bladder tumor are observed, whereas the remaining patients either undergo CRT or surgery depending on the pathologic findings. 27 Studies such as these will help patients delay or even avoid the morbidity of RC and determine optimal CRT treatment regimens for eligible candidates. However, these trials often suffer from challenges with accrual, which may reflect a larger trend nationally. This may be due to the significant percentage of patients with MIBC who do not receive treatment with curative intent or the overall lack of acceptance or experience with BPT in the surgical community. [6] [7] [8] The current study is limited by its retrospective, observational nature. Although we used propensity scorebased matching to reduce the effects of selection bias, accounting for all important measured factors available to us, propensity score methods cannot adjust for unknown confounding (eg, performance status was not an available adjustment). As described above, it is likely that some residual selection bias exists in the results of the current study. In addition, we did not substratify survival outcomes or temporal trends for patients who were given NAC before RC due to its infrequent administration (only 14% of the RC cohort had NAC administered during this time period). Specific limitations of the NCDB include the inability to evaluate the quality of the TUR (including the presence of residual disease). Previous studies have demonstrated that complete TUR improves survival outcomes and has become a tenet of bladder preservation. 28, 29 Furthermore, only OS, not cancer or disease-specific outcomes, can be evaluated in the NCDB. The current study analysis is limited to centers that report to the NCDB and therefore may not be generalizable to the broader population.
Two comparative effectiveness publications also have supported the use and future prospective study of BPT. A Canadian-based group performed a matched propensity score-adjusted analysis in a smaller cohort (112 patients), and demonstrated comparable 5-year diseasespecific survival rates in the RC (73.2%) and trimodal BPT (76.6%) cohorts. 30 In addition, a recently reported inverse probability of treatment weighted-adjusted survival analysis of the NCDB demonstrated worse OS for patients treated with trimodal BPT compared with those receiving RC. 31 It is interesting to note that the observed adverse treatment effect with BPT was found to be diminished in older patients. 31 Although these studies are complementary, the current study has several notable differences. First, the current study had a larger sample size with updated temporal trends. Furthermore, this study highlighted contemporary treatment variations and demonstrated a surprisingly high rate of suboptimal BPT techniques currently used by programs reporting to the NCDB (eg, only 15.5% of patients treated with XRT received concurrent chemotherapy), Moreover, by examining the differences in which BPT can be defined, the current study demonstrates the influence of cohort definition on survival outcomes when performing observational studies, which is a significant limitation. In addition, we used propensity score-matched analyses rather than weighted analyses, such as the method used by Seisen et al, 31 because several studies to date have demonstrated that propensity score matching eliminates a greater percentage of the systematic differences in baseline characteristics between treated and untreated subjects compared with stratification based on the propensity score, covariate adjustment using the propensity score, and inverse probability of treatment weighting. 17 Finally, we also defined survival time from the start of surgery or end of XRT (for the applicable cohorts). This accounts for the immortal time bias associated with the between-group differences in the length of time until treatment was completed and patients became "at risk" for an event (mean time of 5.3 months in the BPT groups vs 2.5 months in the surgery group). This better demonstrates near-term treatment effects when compared with the 3-month landmark analysis used by Seisen et al. 31 It is clear that until level I evidence is available, clinicians will continue to rely on well-designed observational studies to inform contemporary practice. 19 When the findings of the current study are placed into context with the existing comparative evidence base, it illustrates the need for a prospective, randomized trial to adequately address this clinical question.
Conclusions
In the NCDB, the receipt of BPT was found to be associated with decreased OS compared with RC in all patients with stage II to III urothelial carcinoma of the bladder. The use of increasingly stringent definitions of BPT along with more rigorous statistical methods attenuated the observed differences in OS. These trends may be influenced by both measured and unmeasured selection biases. Further randomized prospective controlled trials are needed to compare optimal trimodal BPT with RC to study survival outcomes and to better identify candidates, treatment course, and outcomes of bladder preservation.
